Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

FluoGuide

32.80 SEK

+0.61 %

Less than 1K followers

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.61 %
-0.91 %
-4.37 %
-10.87 %
-17.38 %
-20.58 %
-69.06 %
-76.57 %
+265.86 %

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

Read more
Market cap
536.26M SEK
Turnover
59.27K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.3
2026

General meeting '26

27.5
2026

Interim report Q1'26

25.8
2026

Interim report Q2'26

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release5 hours ago

Notice of Annual General Meeting in FluoGuide A/S

FluoGuide
Press release2/26/2026, 8:45 AM

Redeye: Fluoguide (Q4 Initial take): Key milestones to drive value in 2026

FluoGuide
Press release2/25/2026, 3:33 PM

BioStock: FluoGuide comments on the annual report and road ahead

FluoGuide

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/25/2026, 6:09 AM

FluoGuide A/S publishes annual report for the fiscal year 2025

FluoGuide
Regulatory press release2/25/2026, 6:07 AM

FluoGuide A/S publishes interim report for Q4 2025

FluoGuide
Regulatory press release2/20/2026, 7:40 PM

FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. clinical trial remains on track

FluoGuide
Press release2/19/2026, 8:16 AM

Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026

FluoGuide
Press release1/21/2026, 7:21 AM

FluoGuide submits an IND for FG001, to initiate first U.S. registration trial

FluoGuide
Press release12/19/2025, 10:57 AM

FluoGuide updates IND submission timing for FG001 – trial initiation unaffected

FluoGuide
Press release12/3/2025, 10:29 AM

BioStock: FluoGuide highlights operational progress in Q3

FluoGuide
Press release11/27/2025, 6:56 PM

Redeye: FluoGuide (Q3 review) - Busy news flow

FluoGuide
Regulatory press release11/27/2025, 6:18 AM

FluoGuide A/S publishes Interim Report Q3 2025

FluoGuide
Press release11/25/2025, 1:59 PM

FluoGuide signs collaboration agreement with ZEISS

FluoGuide
Regulatory press release11/24/2025, 3:14 PM

Minutes from Extraordinary General Meeting in FluoGuide A/S

FluoGuide
Press release11/24/2025, 10:05 AM

Invitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 27 November 2025

FluoGuide
Press release11/11/2025, 10:43 AM

BioStock: FluoGuide accelerates precision cancer surgery

FluoGuide
Press release11/5/2025, 4:27 PM

FluoGuide strengthens leadership to advance clinical program and regulatory approval strategy

FluoGuide
Regulatory press release11/5/2025, 4:22 PM

FluoGuide convenes an extraordinary general meeting

FluoGuide
Regulatory press release11/3/2025, 8:54 PM

FluoGuide A/S issue warrants to board members, executive management and employees

FluoGuide
Regulatory press release11/3/2025, 8:30 PM

Share transfer and ownership restructuring – related party transaction

FluoGuide
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.